HealthTech of the Week: Antibodies on Demand: How Genotic is Revolutionizing Biotechnology with AI

In this week’s edition of Healthtech of the Week, we’re spotlighting a true game-changer. In the age of precision medicine and personalized therapies, Polish biotech company Genotic is emerging as a global leader in the transformation of biotechnology. Through a groundbreaking AI-driven approach, Genotic radically shortens the time required to design and produce antibodies, key molecules in modern therapeutics and diagnostics. While traditional methods can take 6 to even 12 months, Genotic’s technology enables the creation of a new, ready-to-use antibody in just 21 days.

At the core of Genotic’s innovation is de novo antibody design, meaning from scratch, with no need for animal use. The entire process happens in silico—in a digital environment—leveraging cutting-edge artificial intelligence models. With its proprietary compute cluster (over 200 GPUs, including NVIDIA H100s—Genotic is a member of the NVIDIA Inception for Startups program), the company can design a new antibody in under 48 hours.

– The designed antibodies are highly specific, capable of binding precisely to a selected antigen epitope, and are engineered to minimize the risk of cross-reactivity. This process eliminates the need for animals, significantly reduces costs, accelerates development, and increases outcome predictability – explains Genotic.

Digital design is a game-changer

Genotic delivers not only antibody designs but also fully validated, ready-to-use products. Thanks to its integrated lab infrastructure, the company produces and validates antibodies in-house, performing a full suite of quality tests—from SDS-PAGE and chromatography to BLI analysis. The result? Approximately 98% of AI-designed projects succeed in yielding functional antibodies—a remarkably high rate.

According to Genotic, digital antibody design is a true industry game-changer. The AI-driven process allows for a lightning-fast transition from the target protein structure to a validated antibody. This process is exceptionally precise, enabling the design of molecules that bind to precisely selected epitopes while minimizing cross-reactivity risks.

A key advantage is safety. Eliminating animal testing entirely and predicting undesirable properties at the digital modeling stage reflects the company’s professionalism. Moreover, this digital-first approach enables substantial cost reductions and full budget predictability. The entire process is also highly scalable, making Genotic’s technology a perfect fit for modern research labs, the pharmaceutical industry, and the future of medicine.

AI as the foundation of success

According to the Healthtech of the Week team, Genotic’s technology has the potential to greatly accelerate the discovery and development of new antibody-based drugs. With the ability to design and test antibodies rapidly and accurately, the company is laying the groundwork for the future of personalized medicine. For instance, in oncology, it becomes possible to design antibodies tailored to the tumor markers of an individual patient—a truly customized solution previously unavailable at scale.

Genotic employs state-of-the-art algorithms inspired by breakthroughs in protein modeling—a field that has even been recognized with a Nobel Prize. These models are continuously learning, analyzing lab data from each newly developed antibody to further improve the platform’s precision and efficacy.

Though headquartered in Poland, Genotic has operated with global ambitions from the beginning. The company is now focusing on expanding into the U.S. and EU markets, responding to growing demand for fast, precise solutions in R&D, diagnostics, and therapy.

Real impact on public health

Of course, scaling AI-driven technology comes with challenges—from expanding computing infrastructure to meeting strict regulatory standards (like CE-IVD for diagnostic applications). But Genotic’s team says they’re ready. With proven technology, their own lab, advanced GPU infrastructure, and an experienced team, they’re well-equipped.

The company’s technology could revolutionize not only therapeutic development but diagnostics as well. Antibodies are increasingly important in diagnostic tools, and their fast, on-demand production is crucial, particularly in rapidly growing fields like Spatial Biology. We have a feeling we’ll be hearing a lot more about Genotic very soon.

—

Stay tuned for more in the “HealthTech of the Week” series, where we’ll continue to uncover fascinating stories from the world of medical technologies that are changing the face of healthcare. If you’re working on an innovative project in the field of new technologies and medicine or want to recommend an interesting solution, contact us at: [email protected].